435 related articles for article (PubMed ID: 32852645)
1. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.
Duarte P; Cuadrado A; León R
Handb Exp Pharmacol; 2021; 264():229-259. PubMed ID: 32852645
[TBL] [Abstract][Full Text] [Related]
2. Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer's and Parkinson's Disease.
Özdemir Z; Alagöz MA; Bahçecioğlu ÖF; Gök S
Curr Med Chem; 2021; 28(29):6045-6065. PubMed ID: 33538661
[TBL] [Abstract][Full Text] [Related]
3. Enzyme Inhibition Assays for Monoamine Oxidase.
Mathew B; Oh JM; Parambi DGT; Sudevan ST; Kumar S; Kim H
Methods Mol Biol; 2024; 2761():329-336. PubMed ID: 38427248
[TBL] [Abstract][Full Text] [Related]
4. [Monoamine oxidase as a target for drug action].
Drozak J; Kozłowski M
Postepy Hig Med Dosw (Online); 2006; 60():498-515. PubMed ID: 17060892
[TBL] [Abstract][Full Text] [Related]
5. Insights into the Mechanism of the Therapeutic Potential of Herbal Monoamine Oxidase Inhibitors in Neurological Diseases.
Mannan A; Singh TG; Singh V; Garg N; Kaur A; Singh M
Curr Drug Targets; 2022; 23(3):286-310. PubMed ID: 34238153
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
Manzoor S; Hoda N
Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
[TBL] [Abstract][Full Text] [Related]
7. A second life for MAO inhibitors? From CNS diseases to anticancer therapy.
Sblano S; Boccarelli A; Mesiti F; Purgatorio R; de Candia M; Catto M; Altomare CD
Eur J Med Chem; 2024 Mar; 267():116180. PubMed ID: 38290352
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants.
Larit F; Elokely KM; Chaurasiya ND; Benyahia S; Nael MA; León F; Abu-Darwish MS; Efferth T; Wang YH; Belouahem-Abed D; Benayache S; Tekwani BL; Cutler SJ
Phytomedicine; 2018 Feb; 40():27-36. PubMed ID: 29496172
[TBL] [Abstract][Full Text] [Related]
9. Monoamine Oxidases.
Edmondson DE; Binda C
Subcell Biochem; 2018; 87():117-139. PubMed ID: 29464559
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase inactivation: from pathophysiology to therapeutics.
Bortolato M; Chen K; Shih JC
Adv Drug Deliv Rev; 2008; 60(13-14):1527-33. PubMed ID: 18652859
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease.
Deshwal S; Di Sante M; Di Lisa F; Kaludercic N
Curr Opin Pharmacol; 2017 Apr; 33():64-69. PubMed ID: 28528298
[TBL] [Abstract][Full Text] [Related]
12. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
13. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
Youdim MB; Bakhle YS
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S287-96. PubMed ID: 16402116
[TBL] [Abstract][Full Text] [Related]
14. A Comprehensive Review of Monoamine Oxidase-A Inhibitors in their Syntheses and Potencies.
Rehuman NA; Mathew B; Jat RK; Nicolotti O; Kim H
Comb Chem High Throughput Screen; 2020; 23(9):898-914. PubMed ID: 32342809
[TBL] [Abstract][Full Text] [Related]
15. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release.
Finberg JP
Pharmacol Ther; 2014 Aug; 143(2):133-52. PubMed ID: 24607445
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Structure-Activity Relationship (QSAR) Studies for the Inhibition of MAOs.
Ramesh M; Muthuraman A
Comb Chem High Throughput Screen; 2020; 23(9):887-897. PubMed ID: 32208114
[TBL] [Abstract][Full Text] [Related]
17. Selective MAO-B inhibitors: a lesson from natural products.
Carradori S; D'Ascenzio M; Chimenti P; Secci D; Bolasco A
Mol Divers; 2014 Feb; 18(1):219-43. PubMed ID: 24218136
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor design for monoamine oxidases.
Ramsay RR
Curr Pharm Des; 2013; 19(14):2529-39. PubMed ID: 23116392
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors.
Ramesh M; Dokurugu YM; Thompson MD; Soliman ME
Comb Chem High Throughput Screen; 2017; 20(6):492-509. PubMed ID: 28294055
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
Nagatsu T; Sawada M
J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
